2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Biological Processes, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Genetic Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pregnant, Animal Model
PAPER

4650 Predictors of response to intravenous ferumoxytol therapy in pregnancy

Rupsa C Boelig, MD, Fran Dipietro2, Michael Auerbach, MD3, Richard Derman, MD4
1 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
2 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
3 Georgetown University, Washington DC, United States
4 Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Background: Although intravenous iron is the most effective treatment for iron deficiency anemia in pregnancy, a significant proportion of patients will remain anemic by delivery despite a complete course of ferumoxytol (510mg x2 doses) in pregnancy.

Objective: Identify baseline characteristics associated with response to intravenous ferumoxytol administered in the second trimester of pregnancy.

Methods:  This is a secondary analysis of a randomized controlled trial (NCT04278651). We included those who were randomized to and received intravenous iron. For the primary trial, participants were eligible if they had anemia with Hb 9.0-10.9 and iron deficiency based on ferritin<30ng/ml OR total iron saturation (TSAT)<20%. Participants were randomized and received treatment intervention in the second trimester (16 0/7 – 27 6/7 weeks). For this secondary analysis, the primary outcome for response to IV iron is achieving anemia resolution (Hb≥11.0g/dL) at 90d post treatment; secondary outcome was change from baseline Hb at 90 days. Predictors examined were maternal age (years), and BMI (kg/m2), baseline hemoglobin (g/dL), ferritin (ng/ml), and total iron saturation (TSAT, %). Multivariable logistic regression with backward selection was conducted with p<0.10 used to retain predictors in each step and p<0.05 considered significant. Results presented as mean difference (MD), assuming unequal variance, or adjusted odds ratio (aOR) with 95% confidence intervals.

Results: Of 40 randomized to IV iron in the primary trial, 2 withdrew, and 2 crossed-over, and 3 did not have 90 day data available, thus N=33 patients included in this analysis with n=27 (82%) achieving anemia resolution by 90 days. The study population included 69% Black, 8% White, 17% Hispanic/White, and 6% Hispanic/Black. Of those who did not achieved anemia resolution at 90days vs did, baseline characteristics were similar except a significant difference in baseline ferritin (55.8±30.8 vs 14.8±8.6, MD 41.10 (-73.3 to -8.7), p=0.02). In multivariable linear regression analysis, only baseline ferritin remained significantly, negatively, associated with achieving anemia resolution by 90days (aOR 0.90 (0.82-0.98)). In multivariable linear regression analysis examining change in Hb from baseline to 90d, both baseline Hb (Beta -0.81 (-1.1 to -0.55)) and baseline ferritin (Beta -0.02 (-0.04 to -0.01) were significantly associated with change in Hb from baseline.

Conclusion: Higher baseline ferritin in patients with iron deficiency anemia is associated with reduced likelihood of achieving anemia resolution by 90 days post-treatment with IV ferumoxytol. Given all participants had similar TSAT, the high ferritin likely reflects baseline inflammatory state that may interfere with iron storage and mobilization despite IV iron therapy. Similarly higher Hb may reflect relative hemoconcentration rather than non-anemia, which is also associated with inflammatory states. Close follow up of therapy response and assessment/treatment of inflammatory conditions (ie infection) may improve IDA treatment response in pregnancy.

Rupsa C Boelig, MD: COVIS Pharma - Research Funding